文献速递消化道肿瘤与早癌消化内镜

788例T1期直肠类癌患者的转移患病率与生存分析

Prevalence of metastasis and survival of 788 patients with T1 rectal carcinoid tumors.
PubMed 文献 · Gastrointest Endosc · 2018-11-14

基于美国SEER数据库纳入788例直径<2 cm的T1期直肠类癌患者,分析初诊时转移患病率及生存。肿瘤≤10 mm者转移患病率为1.1%,11-19 mm者为6.6%(P = .01);无转移者5年癌症特异性生存率显著优于有转移者(100% vs 78%,P < .001)。≤10 mm的T1N0M0患者中,局部切除与根治性手术的5年癌症特异性生存率均为100%。

要点

  • T1期直肠类癌11-19 mm者转移患病率6.6%,高于≤10 mm者的1.1%(P = .01)。
  • 无转移者5年癌症特异性生存率100%,有转移者78%(P < .001)。
  • ≤10 mm的T1N0M0直肠类癌局部切除后5年癌症特异性生存率达100%。

核心结论

  • 较大的T1期直肠类癌(11-19 mm)较≤10 mm者淋巴结转移风险显著更高,转移者生存更差。
  • 对于≤10 mm的T1N0M0直肠类癌,局部治疗已足够,长期结局极佳。

研究设计与样本

  • 基于美国监测、流行病学和最终结果(SEER)数据库的回顾性分析,纳入788例直径<2 cm的T1期直肠类癌患者。

主要发现

  • 727例(92.3%)肿瘤直径≤10 mm,61例(7.7%)为11-19 mm。
  • 12例(1.5%)初诊时即有转移,≤10 mm者转移患病率1.1%,11-19 mm者6.6%(P = .01)。
  • 无转移者5年癌症特异性生存率100%,有转移者78%(P < .001)。
  • 559例≤10 mm的T1N0M0患者中,局部切除与根治性手术的5年癌症特异性生存率均为100%。

关键数值与推荐

  • 肿瘤≤10 mm者转移患病率1.1%,11-19 mm者6.6%(P = .01)。
  • 无转移者5年癌症特异性生存率100%,有转移者78%(P < .001)。
  • ≤10 mm的T1N0M0患者局部切除与根治性手术的5年癌症特异性生存率均为100%。

临床怎么用

  • 对于≤10 mm的T1N0M0直肠类癌,局部治疗(内镜下或经肛切除)可达到与根治性手术相同的5年癌症特异性生存率。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Prevalence of rectal carcinoids is increasing, partly because of increased colorectal cancer screening. Local excision (endoscopic or transanal excision) is usually performed for small (<1-2 cm) rectal carcinoids, but data on clinical outcomes from large population-based U.S. studies are lacking. The aims of this study were to determine the prevalence of metastasis of resected small rectal carcinoid tumors using a large national cancer database and to evaluate the long-term survival of patients after local resection as compared with radical surgery. METHODS: The Surveillance Epidemiology and End Results database was used to identify 788 patients with rectal T1 carcinoids <2 cm in size. Prevalence of metastases at initial diagnosis and risk factors for metastases were analyzed. Cancer-specific survival (CSS) was calculated. RESULTS: A total of 727 patients (92.3%) had tumors ≤10 mm in diameter and 61 (7.7%) had tumors 11 to 19 mm. Overall, 12 patients (1.5%) had metastasis at the time of diagnosis with prevalence of 1.1% in lesions ≤10 mm and 6.6% in lesions 11 to 19 mm (P = .01). Survival of patients with T1 rectal carcinoids without metastasis was significantly better than those with metastasis (5-year CSS of 100% vs 78%, P < .001). Of 559 patients with T1N0M0 rectal carcinoids ≤10 mm, 5-year CSS was 100% in both groups who underwent local excision and those who underwent radical surgery. CONCLUSIONS: Larger T1 rectal carcinoid tumors (11-19 mm) have significantly higher risk of lymph node metastases compared with those ≤10 mm. Survival is worse with metastatic disease. Local therapy is adequate for T1N0M0 rectal carcinoids ≤10 mm in size with excellent long-term outcomes.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Ngamruengphong S, Kamal A, Akshintala V, et al. Prevalence of metastasis and survival of 788 patients with T1 rectal carcinoid tumors. Gastrointest Endosc. 2018. PMID: 30447216. doi:10.1016/j.gie.2018.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。